Sulphonylureas use raises risk of death

More evidence has emerged to support downgrading sulphonylureas from second- to third-line therapy when NICE reviews glitazones for type-2 diabetes later this year.

A Canadian study has confirmed the results of previous trials that indicated that sulphonylureas put patients at increased risk of serious cardiovascular events.

The researchers looked at data from 4,138 patients on sulphonylurea monotherapy, 120 patients on a first-generation drug and 1,537 patients on metformin.

The data showed that the risk of death increased with exposure to sulphonylureas.

However, patients on the highest doses of metformin had a 20 per cent decreased risk of death compared with patients on the lowest doses.

The newer sulphonylurea glyburide (Gliben) was found to be safer than the older drugs. High exposure to glyburide increased mortality by 30 per cent, while high doses of the older drugs chlorpropamide (Diabinese) and tolbutamide (Rastinon) more than doubled it.

Dr Peter Tasker, a GP in Kings Lynn, Norfolk, said that the use of sulphonylureas in the treatment of type-2 diabetes needed to be reviewed. He said: 'The big message is to stop using older sulphonylureas altogether, and where possible use metformin.'

CMAJ 2006; 174(2):169-174

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Subject access requests to GP practices increased by a third under GDPR

Subject access requests to GP practices increased by a third under GDPR

The number of subject access requests (SARs) GP practices receive each month has...

RCGP criticises GP at Hand video showing antibiotics prescribed for sore throat

RCGP criticises GP at Hand video showing antibiotics prescribed for sore throat

A promotional video for Babylon GP at Hand that shows a patient with a sore throat...

Review into overprescribing aims to give GPs power to challenge hospital scrips

Review into overprescribing aims to give GPs power to challenge hospital scrips

A government review of overprescribing in the NHS could see GPs given more power...

Submit your session ideas for the RCGP Annual Conference 2019

Submit your session ideas for the RCGP Annual Conference 2019

GPs can now submit ideas for sessions at the RCGP Annual Conference in Liverpool,...

Scottish GP workforce increases for first time in 10 years, figures show

Scottish GP workforce increases for first time in 10 years, figures show

GP numbers in Scotland have risen slightly for the first time in 10 years despite...

More than 16m GP practice appointments a year lost to DNAs

More than 16m GP practice appointments a year lost to DNAs

More than 16m appointments at GP practices are lost every year because patients fail...